InsiderTrades.com logo

ALIM Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 31.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Alimera Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Alimera Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alimera Sciences Share Price & Price History

Current Price: $5.54
Price Change: +0.30 (1.20%)
As of 04/8/2026 01:00 AM ET

This chart shows the closing price history over time for ALIM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Alimera Sciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2023Caligan Partners LpMajor ShareholderBuy579,000$3.39$1,962,810.0016,835,154View SEC Filing Icon  
5/17/2023Adam MorganDirectorBuy1,401,901$1.70$2,383,231.701,659,654View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Alimera Sciences (NASDAQ:ALIM)

99.83% of Alimera Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALIM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alimera Sciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/21/2024Stonepine Capital Management LLC3,511,816$19.53M17.8%-13.3%6.703%Search for SEC Filing on Google Icon
8/14/2024Glazer Capital LLC551,533$3.07M0.2%N/A1.053%Search for SEC Filing on Google Icon
8/14/2024Gabelli Funds LLC108,000$0.60M0.0%N/A0.206%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC181,694$1.01M0.0%+3.9%0.347%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers20,394$0.11M0.0%N/A0.039%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp61,907$0.34M0.0%N/A0.118%Search for SEC Filing on Google Icon
7/16/2024Deltec Asset Management LLC124,169$0.69M0.1%N/A0.237%Search for SEC Filing on Google Icon
5/16/2024Ancora Advisors LLC234,620$0.92M0.0%N/A0.448%Search for SEC Filing on Google Icon
5/11/2024Hillsdale Investment Management Inc.43,400$0.17M0.0%N/A0.083%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.1,045,460$4.08M0.0%+61.1%1.996%Search for SEC Filing on Google Icon
5/2/2024Fifth Lane Capital LP21,238$83K0.1%N/A0.041%Search for SEC Filing on Google Icon
2/13/2024Stonepine Capital Management LLC3,999,459$17.28M7.5%+0.4%7.630%Search for SEC Filing on Google Icon
2/12/2024AIGH Capital Management LLC2,226,068$9.62M3.8%-6.2%4.247%Search for SEC Filing on Google Icon
2/9/2024Worth Venture Partners LLC556,642$2.41M1.3%-6.2%1.062%Search for SEC Filing on Google Icon
11/15/2023Worth Venture Partners LLC593,709$1.84M1.1%N/A1.133%Search for SEC Filing on Google Icon
11/14/2023Stonepine Capital Management LLC3,983,686$12.35M4.1%N/A7.600%Search for SEC Filing on Google Icon
11/13/2023AIGH Capital Management LLC2,372,572$7.36M3.5%N/A4.526%Search for SEC Filing on Google Icon
8/14/2023Perritt Capital Management Inc.10,000$29K0.0%-44.4%0.114%Search for SEC Filing on Google Icon
8/11/2023Velan Capital Investment Management LP1,659,654$4.85M4.5%+543.9%18.838%Search for SEC Filing on Google Icon
2/16/2023Caligan Partners LP478,777$1.30M1.0%N/A6.840%Search for SEC Filing on Google Icon
11/15/2022Perritt Capital Management Inc.18,000$91K0.1%-34.3%0.257%Search for SEC Filing on Google Icon
5/12/2022Healthcare of Ontario Pension Plan Trust Fund250,000$1.40M0.0%N/A3.575%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC497,639$2.55M0.8%-0.7%7.173%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alimera Sciences logo
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Read More on Alimera Sciences

Today's Range

Now: $5.54
Low: $5.54
High: $5.54

50 Day Range

MA: $5.55
Low: $5.19
High: $5.60

52 Week Range

Now: $5.54
Low: $2.61
High: $5.65

Volume

N/A

Average Volume

376,318 shs

Market Capitalization

$290.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of Alimera Sciences?

Alimera Sciences' top insider investors include:
  1. Caligan Partners Lp (Major Shareholder)
  2. LP Bavp (Major Shareholder)
  3. Adam Morgan (Director)
  4. C Daniel Myers (CEO)
  5. Richard S Eiswirth Jr (Insider)
  6. Kenneth Green (SVP)
  7. Philip Ashman (SVP)
  8. Richard S Eiswirth, Jr (CFO)
  9. Philip Ashman (COO)
  10. John Snisarenko (Director)
Learn More about top insider investors at Alimera Sciences.

Alimera Sciences Active Insiders

Richard S Eiswirth Jr
Richard S Eiswirth Jr (Age 58)
CEO
Philip Ashman
Philip Ashman (Age 61)
COO
John Philip Jones
John Philip Jones
CFO
James R Largent
Director